Katie Parker

Publications

• Nogova, L., Sequist, L.V., Perez Garcia, J.M., Andre, F., Delord, J.P., Hidalgo, M., Schellens, J.H., Cassier, P.A., Camidge, D.R., Schuler, M. and Vaishampayan, U., 2016. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. Journal of Clinical Oncology, 35(2), pp.157-165.

• Sharma S, De Vries EG, Infante JR, Oldenhuis CN, Gietema JA, Yang L, Bilic S, Parker K, Goldbrunner M, Scott JW, Burris HA. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investigational new drugs. 2014 Feb 1;32(1):135-44.

• Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. British journal of haematology. 2009 Oct 1;147(1):97-101.

Global Experts from India

Global Experts in Subject